Warning letter
Medpointe Healthcare, Inc.: warning letter of Jul 22, 2002
FDA warning letter UCM145025 · New Jersey District Office
Key facts
| Reference number | UCM145025 |
|---|---|
| Company | Medpointe Healthcare, Inc. |
| Subject | CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or Holding/Adulterated |
| Issue date | Jul 22, 2002 |
| Posted date | Jul 22, 2002 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.67, 211.110, 211.192, 211.65(b) |
| Country | 3 |
| Inspection city | Cranbury |
| Inspection ZIP | 08512 |
| Inspection start date | May 20, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: